Turn Therapeutics

TTRX · NASDAQ

$10.47−$0.27 (−2.51%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $10.74

About TTRX

Turn Therapeutics, Inc. is a pharmaceutical and medical device development company. The company is headquartered in Westlake Village, California. The company went IPO on 2025-10-08. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.

Employees: 0
Headquarters: Westlake Village, California
Listed: Oct 8, 2025
Sector: Health Care
Industry: Pharmaceuticals
Website: turntherapeutics.com

Leadership

Turn Therapeutics executives
Name	Title	Since	Age
Bradley Burnam	—	2018	46
Zuraiz Chaudhary	—	—	30
Neilesh Ghodadra	—	2018	45
Martin Dewhurst	—	—	62
Andrew Gengos	—	—	60
Arthur Golden	—	—	79
Kent Kester	—	—	65

Similar companies

Companies in the same industry as Turn Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.